Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux

Status Completed

Clinical Trial Summary

High-efficiency post-dilution online hemodiafiltration (OL-HDF) using high-flux dialyzer and requiring high blood flow rate (BF ≥400 mL/min) has been reported to enhance protein-bound toxin and middle molecular toxin removal and improve patient survival. Unfortunately, the majority of patients could not reach that high BF because of vascular access issue. This randomized crossover study was conducted to compare these uremic toxin removals between the new modality (limited BF OL-HDF with super high-flux dialyzer) and the control (high-efficiency OL-HDF). The OL-HDF patients were randomized to undergo either new modality or control for 2 weeks before crossover to the other modality for another 2 weeks.

Clinical Trial Description

Elevated protein-bound toxins including p-cresol (pCS) and indoxyl sulfate (IDS) as well as middle-molecular toxins such as beta2-microglobulin (B2M) which could not be removed by hemodialysis (HD) are obviously correlated with high mortality. High-efficiency post-dilution online hemodiafiltration (OL-HDF) using high-flux dialyzer and requiring high blood flow rate (BF ≥400 mL/min) has been reported to enhance pCS, IDS, and B2M removal and improve patient survival. Unfortunately, the majority of patients could not reach that high BF because of vascular access issue. We innovated the OL-HDF modality for this limited BF situation by integrating the novel super high-flux membrane dialyzer (SHF; PES-17Dα, Nipro Corporation, Japan) into pre-dilution OL-HDF. This randomized crossover study was conducted to compare the uremic toxin removals between the new modality (limited BF OL-HDF with SHF) and the control (high-efficiency OL-HDF). The OL-HDF patients were randomized to undergo either new modality or control for 2 weeks before crossover to the other modality for another 2 weeks. Removals of pCS and IDS as well as small and middle molecule toxins were compared. The pCS and IDS were measured by high performance liquid chromatography. The dialysate albumin loss and patient safety were also monitored. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03288922
Study type	Interventional
Source	Chulalongkorn University
Contact
Status	Completed
Phase	N/A
Start date	October 2016
Completion date	January 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04892745` - Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance
Not yet recruiting	`NCT04925674` - Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.	Phase 1
Active, not recruiting	`NCT03183245` - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis	Phase 3
Completed	`NCT03365635` - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C	Phase 4
Withdrawn	`NCT02904343` - Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study	N/A
Withdrawn	`NCT01855334` - L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD	Phase 4
Completed	`NCT01700465` - Estimating and Predicting Hemodynamic Changes During Hemodialysis	N/A
Recruiting	`NCT01195519` - The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis	N/A
Completed	`NCT00737672` - GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis	Phase 3
Completed	`NCT00527774` - Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients	N/A
Completed	`NCT00942253` - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)	Phase 2
Completed	`NCT00224081` - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)	Phase 4
Completed	`NCT00850252` - Use of a Lifeline Graft in the A-V Shunt Model	Phase 1/Phase 2
Completed	`NCT00776750` - Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients	Phase 4
Recruiting	`NCT06351007` - Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK)	N/A
Withdrawn	`NCT03664141` - Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study)	Phase 3
Completed	`NCT03909698` - Antibiotic Dosing in Patients on Intermittent Hemodialysis
Recruiting	`NCT03311321` - Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients	N/A
Recruiting	`NCT06098924` - HD Patients' Depression and Happiness
Recruiting	`NCT03419923` - Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms